Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCN01 for periocular region prepping
NCT01853722Phase 2
Key facts
- Status
- Completed
- Start
- Apr 2013
- Primary completion
- Jul 2013
- Countries
- 1
- Sponsor
- Deacon Biosciences
- Modality
- Small Molecules
- Drugs
- DCN-01
- Conditions
- ocular infection
01
Overview
Phase 2, randomised, open-label trial of DCN-01 in ocular infection (2 arms), sponsored by Deacon Biosciences. Primary endpoint: Change from baseline in periocular region bacterial load. Started Apr 2013; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
DCN01
DCN01: Three serial applications per periocular region.
Unisol
Unisol: Three serial applications per periocular region.
03
Who it enrols
Healthy volunteers with no active infection or known sensitivities to the study medication.
04
Endpoints
Primary
Change from baseline in periocular region bacterial load
Secondary
Proportion of periocular regions with a reduction from baseline in bacterial load
Beyond the preview
Go deeper on NCT01853722.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01853722.